This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: D68.2 | Special Copayment Reduction: V009 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | Rare clotting factor deficiency, Rare bleeding disorder (RBD), other hereditary clotting factor deficiency |
| C. Adult onset | Varies by factor type — overall, severe forms are mostly found in childhood and mild forms in adulthood. Mild FVII deficiency after procedures in adulthood, FXII deficiency asymptomatic for life, FXIII deficiency in the neonatal period |
| 1. History | Establishment of the WFH rare bleeding disorder classification and development of the EN-RBD international registry |
| 2. Causes | Pathogenic variants in each of the FI, FII, FV, FVII, FX, FXII, and FXIII genes |
| 3. Genetics | Mostly autosomal recessive inheritance; gene locations vary by factor |
| 4. Epidemiology | Ultra-rare, at 0.5–2 per 1 million population for each deficiency type |
| 5. Pathophysiology | Heterogeneous mechanisms according to the position of each factor in the coagulation pathway |
| 6. Symptoms | Comparison of bleeding phenotypes by factor: thrombosis-bleeding paradox of fibrinogen deficiency, umbilical cord bleeding in FXIII deficiency, etc. |
| 7. Signs | Factor-specific patterns of coagulation test abnormalities |
| 8. Screening | PT, APTT, TT, fibrinogen quantification, FXIII screening |
| 9. Diagnosis | Factor-specific activity quantification and molecular genetic testing |
| 10. Treatment | FFP, PCC, factor-specific concentrates, recombinant FVIIa |
| 11. Prognosis | Differs greatly by factor type, severity, and access to treatment |
| 12. Prevention | Avoidance of consanguineous marriage, genetic counseling, preoperative prophylactic treatment |
| 13. References | Peyvandi F et al. (2012) Haemophilia … and 11 other papers |
Whereas hemophilia A (FVIII deficiency, D66), hemophilia B (FIX deficiency, D67), and FXI deficiency (D68.1) were each given independent ICD codes, the other clotting factor deficiencies have long been grouped under a single category code, D68.2. This code covers deficiencies of fibrinogen (FI), prothrombin (FII), FV (proaccelerin), FVII, FX (Stuart-Prower factor), FXII (Hageman factor), and FXIII (fibrin-stabilizing factor). Grouping them under the same code even though each deficiency shows an entirely different clinical phenotype is the product of an administrative compromise arising from the extreme rarity of these diseases.
The World Federation of Hemophilia (WFH), in its 2005 guidelines, collectively classified these as 'Rare Bleeding Disorders (RBD)'. This concept is of great academic and clinical significance in that it led to recognizing rare clotting factor deficiencies other than hemophilia A and B as a single clinical group.
From the early 2000s, the European Network of Rare Bleeding Disorders (EN-RBD) was formed, centered on the Maggiore Policlinico Hospital in Milan, Italy. This network, with the participation of 66 hemophilia centers in 13 countries, systematically collects data on patients with fibrinogen deficiency, FII deficiency, FV deficiency, FVII deficiency, FX deficiency, and FXIII deficiency. The EN-RBD database provides the most extensive evidence on the clinical features of RBDs, bleeding scores (ISTH-BAT, MCMDM-1VWD bleeding score), and treatment outcomes, and has produced dozens of important papers since 2012.
In its revised 2021 guidelines, the WFH presented individualized treatment recommendations for each factor deficiency among the RBDs. In particular, it describes how the treatment paradigm has changed greatly, reflecting the emergence of recombinant factor concentrates, the widespread use of tranexamic acid, and progress in gene therapy research. In Korea, through the rare disease helpline and the National Health Insurance Special Copayment Reduction program, patients with D68.2 code diseases receive the benefit of a 10% copayment for 5 years after V009 registration.
The causes of the clotting factor deficiencies covered by the D68.2 code are pathogenic variants occurring in a different gene for each factor. They commonly follow an autosomal recessive mode of inheritance, and prevalence is markedly higher in populations with a high frequency of consanguineous marriage (Iran, Pakistan, southeastern Turkey, etc.).
All deficiency types that make up D68.2 are caused by variants in genes located on autosomes, and the mode of inheritance is autosomal recessive. That is, they are fundamentally different from the X-linked hemophilias A and B in that they occur with equal frequency in men and women. Heterozygous carriers are usually asymptomatic or show only a mild bleeding tendency.
| Deficient factor | Gene | Chromosomal location | Main variant types |
|---|---|---|---|
| Fibrinogen (FI) | FGA, FGB, FGG | 4q28 | Missense, nonsense, splicing |
| Prothrombin (FII) | F2 | 11p11.2 | Mainly missense |
| FV (proaccelerin) | F5 | 1q24.2 | Various (deletions, missense, etc.) |
| FVII | F7 | 13q34 | Mainly missense (more than 300 reported) |
| FX (Stuart factor) | F10 | 13q34 | Missense, nonsense |
| FXII (Hageman factor) | F12 | 5q35.3 | p.Thr328Lys (Western European founder) |
| FXIII-A | F13A1 | 6p25.1 | Population-specific founder variants |
| FXIII-B | F13B | 1q31.3 | Missense, deletions |
In regions with a high frequency of consanguineous marriage, such as Iran, southeastern Turkey, and Pakistan, the prevalence of each D68.2 type is markedly higher than the global average. In Iran, FVII deficiency and FXIII deficiency are reported with particularly high frequency, and unique founder variants have been identified in each population. In Korea, consanguineous marriage is infrequent, so these deficiencies are very rare, and most are reported in the form of sporadic cases.
The prevalence of each deficiency within the D68.2 category is uniformly very low. According to WFH Global Survey data (as of 2023), the number of registered RBD patients worldwide is estimated as follows.
| Deficient factor | Estimated prevalence (per 1 million) | Notes |
|---|---|---|
| FVII deficiency | ~2 | Most common within D68.2 |
| FX deficiency | ~1 | Life-threatening when severe |
| FV deficiency | ~1 | Parahemophilia |
| Fibrinogen deficiency | ~1 | Afibrinogenemia, hypofibrinogenemia, and dysfibrinogenemia combined |
| FXIII deficiency | ~0.5 | Diagnosed by umbilical cord bleeding in the neonatal period |
| FII deficiency | ~0.5 | Extremely rare |
| FXII deficiency | ~1 | No bleeding symptoms |
In Korea, D68.2 diseases can be tracked when registered under National Health Insurance Special Copayment Reduction V009, but a complete count is difficult. Unlike hemophilia, there is no national registry database, so the actual prevalence may be higher than estimates. Case reports from hematology departments of tertiary general hospitals are published sporadically, and FVII deficiency and FXIII deficiency are estimated to account for relatively high proportions. Given the social characteristic that consanguineous marriage is rare, compound heterozygous variants are expected to be common.
Because the factors in the D68.2 category are located at different points in the coagulation cascade, the mechanistic abnormalities that appear with deficiency also differ by factor. In the extrinsic pathway, FVII is activated by binding with tissue factor (TF) and directly activates FX. Therefore, in FVII deficiency, only PT is prolonged. In the common pathway, FX, FV, prothrombin (FII), fibrinogen (FI), and FXIII act sequentially. In FX, FV, and FII deficiency, both APTT and PT are prolonged, and in fibrinogen deficiency, TT is also prolonged.
FXII deficiency occurs at the contact activation step of the intrinsic pathway, but sufficient evidence has accumulated that FXII plays a minimal role in in vivo hemostasis, so patients with FXII deficiency have no bleeding symptoms. FXIII, after being activated by thrombin, stabilizes the clot by cross-linking fibrin monomers; in deficiency, a characteristic phenotype appears in which a normal clot initially forms but dissolves within a few hours.
Instead of artificially separating the extrinsic and intrinsic pathways, the modern cell-based model of coagulation views the coagulation process in three phases: tissue factor-expressing cells (initiation phase), platelets (amplification and propagation phase), and fibrinogen-fibrin conversion (stabilization phase). In this model, the clinical phenotype of each D68.2 factor deficiency is determined by which phase—initiation, amplification, or stabilization—it affects. The fact that PT and APTT are normal in FXIII deficiency, because it affects only the stabilization phase, is clearly explained by this model.
In the D68.2 group, bleeding phenotypes differ greatly by factor type. In FXIII deficiency, umbilical cord bleeding in the neonatal period is a virtually diagnostically specific symptom. Bleeding that persists from a few hours after the umbilical cord is tied just after birth occurs in more than 90% of severe FXIII deficiency, and this symptom alone should raise strong suspicion of FXIII deficiency. The risk of intracranial hemorrhage is also markedly higher than in other RBDs.
In fibrinogen (FI) deficiency, a paradoxical phenotype in which bleeding and thrombosis occur simultaneously is observed. Arterial or venous thrombosis is reported in 10–20% of patients with afibrinogenemia, which is explained by fibrinogen's function of adsorbing thrombin and regulating excessive thrombin activity (thrombin-buffering role). FVII deficiency is the most common within D68.2 but has the greatest clinical heterogeneity. Spontaneous joint bleeding occurs even in severe deficiency with FVIIa activity below 1%, whereas mild deficiency is sometimes found incidentally after surgery in adulthood.
In all deficiencies in the D68.2 category, female patients have an increased risk of menorrhagia, miscarriage during pregnancy, and postpartum hemorrhage at delivery. In particular, in women with fibrinogen deficiency, recurrent miscarriage (habitual abortion) is an important clinical problem, and fibrinogen replacement therapy is needed to maintain pregnancy. In women with FXIII deficiency as well, FXIII is essential for maintaining pregnancy, so prophylactic administration of FXIII concentrate is recommended.
Initial differentiation of each D68.2 factor deficiency is made from the combination of PT, APTT, thrombin time (TT), and fibrinogen quantification results. Isolated PT prolongation strongly suggests FVII deficiency. Simultaneous prolongation of APTT and PT indicates common pathway (FX, FV, FII) or fibrinogen deficiency. If TT prolongation accompanies it, consider a fibrinogen abnormality (quantitative decrease or functional abnormality). If APTT is markedly prolonged but PT is normal and there is no bleeding, suspect FXII deficiency. If PT, APTT, and TT are all normal but there is bleeding, FXIII deficiency must be excluded.
The classic screening test for FXIII deficiency is the 5M urea clot solubility test. In this test, clots from patients with severe FXIII deficiency dissolve in urea solution within a few minutes, whereas normal clots remain stable for more than 24 hours. However, this method is positive only when FXIII activity is below 3%, so false negatives occur in intermediate (mild) deficiency. Currently, quantitative FXIII activity assay (chromogenic substrate method) is used as the standard.
In patients with bleeding or when a coagulation abnormality is suspected before surgery, first-line screening tests consist of PT, APTT, thrombin time (TT), fibrinogen quantification, platelet count, and platelet function tests. Applying an algorithm that estimates the position of the deficient factor from the combined pattern of these results can narrow the scope of subsequent testing. In particular, isolated PT prolongation suggests FVII deficiency or early vitamin K deficiency, and simultaneous PT and APTT prolongation suggests a common pathway or fibrinogen problem.
The BAT (Bleeding Assessment Tool), the standardized bleeding score of the International Society on Thrombosis and Haemostasis (ISTH), is useful for objectively quantifying the bleeding tendency of RBD patients. A BAT score of ≥3 in adult men, ≥5 in adult women, and ≥2 in children is judged to indicate a significant bleeding tendency. This tool is used to screen patients suspected of rare clotting factor deficiency and to establish treatment plans according to bleeding severity.
Confirmation of a D68.2 diagnosis is made through an activity quantification assay of the relevant factor. For example, when FVII deficiency is suspected, an FVII chromogenic or clotting activity assay is performed, and when FXIII deficiency is suspected, FXIII activity quantification (chromogenic substrate method) and FXIII antigen measurement are performed together. Fibrinogen abnormalities are classified into quantitative deficiency and functional abnormality by comparing the results of the Clauss method (functional fibrinogen) and immunoassay (antigen).
Molecular genetic confirmation can be made through an NGS-based clotting factor panel or whole exome analysis, and in consanguineous families in particular, homozygous variants can be searched for efficiently. When prenatal diagnosis is planned, it is performed together with parental carrier testing.
The WFH 2021 guidelines present severity classification criteria for each RBD according to factor activity level. For example, FVII deficiency is classified as <1% (severe), 1–10% (moderate), and >10% (mild), and FXIII deficiency as <1% (severe) and 1–30% (moderate). This severity classification is the basis for determining treatment intensity and applying prophylactic dosing protocols.
The basic treatment for each D68.2 factor deficiency is administration of fresh frozen plasma (FFP), but more specific products exist for certain factors. Prothrombin Complex Concentrate (PCC) supplies FII, FVII, FIX, and FX simultaneously, so it can be used to treat FII, FVII, and FX deficiencies. Recombinant activated FVIIa (rFVIIa) is a specific treatment for FVII deficiency that can directly replace FVII activity without the risk of thrombotic complications, and is used for treating bleeding and for preoperative prophylaxis.
For FXIII deficiency, plasma-derived FXIII concentrate (Corifact) and recombinant FXIII (Tretten, catridecacog) are approved. These can effectively prevent bleeding with once-monthly prophylactic administration. For fibrinogen deficiency, fibrinogen concentrates (Riastap, Haemocomplettan, etc.) are used. For FVII deficiency, recombinant FVIIa (NovoSeven) is the most important specific treatment. In FV deficiency, because platelets are rich in FV, platelet transfusion is recommended as adjunctive treatment for severe bleeding.
The prognosis of the D68.2 group varies greatly depending on the type and severity of the deficient factor. FXII deficiency carries no bleeding risk, so its prognosis is very good. In contrast, in severe FXIII deficiency, the risk of intracranial hemorrhage persists throughout life, and without prophylactic treatment it can lead to fatal outcomes. Severe FVII deficiency also carries risks of spontaneous joint bleeding and intracranial hemorrhage, requiring periodic prophylactic treatment.
Another factor determining the prognosis of RBDs is access to treatment. In developed countries, access to specific factor concentrates is easy, but in low- and middle-income countries FFP is often the only treatment option. According to the WFH Global Survey, a considerable number of RBD patients worldwide are undiagnosed or receive inadequate treatment, leading to unnecessary increases in morbidity and mortality. In Korea, the burden of medical expenses is reduced through the Special Copayment Reduction program, but securing insurance coverage for some specific concentrates remains a challenge.
Primary prevention of D68.2 category diseases is to avoid consanguineous marriage and, when there is already a patient in the family, to determine carrier status through genetic counseling. In particular, when both parents are carriers, each pregnancy has a 25% probability of producing a homozygous or compound heterozygous affected child. It is possible to determine the fetal genotype through prenatal genetic testing (CVS or amniocentesis).
In severe FXIII deficiency and some severe FVII deficiency, regular prophylactic factor administration (prophylaxis) is effective in preventing serious bleeding complications such as intracranial hemorrhage. When surgery, invasive procedures, or delivery are planned, factor correction targets, dosing schedules, and monitoring plans should be established in advance in consultation with a specialist in the relevant factor. Tranexamic acid is considered as an adjunct in all RBD patients at risk of mucosal bleeding.